FOXA1 Antibody [FOXA1/1512] | 33-659

FOXA1 Antibody [FOXA1/1512] | 33-659 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: A human partial recombinant protein corresponding to amino acids 372-472 was used as the immunogen for this FOXA1 antibody.

Research Area: Stem Cell

Tested Application: Flow, IHC, IF, WB

Application: Flow Cytometry: 0.5-1ug/10^6 cells
IF: 1-2 ug/ml
WB: 0.5-1 ug/ml
IHC (FFPE) : 1-2 ug/ml for 30 min at RT
Optimal dilution of the FOXA1 antibody should be determined by the researcher.

Specificiy: Does not react with rat

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: FOXA1/1512

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: FOXA1 Antibody: HNF3A, TCF3A, HNF3A, Hepatocyte nuclear factor 3-alpha, Forkhead box protein A1, HNF-3-alpha

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: FOXA1 is a member of the forkhead class of DNA-binding proteins. These hepatocyte nuclear factors are transcriptional activators for liver-specific transcripts such as albumin and transthyretin, and they also interact with chromatin as a pioneer factor. Similar family members in mice have roles in the regulation of metabolism and in the differentiation of the pancreas and liver.

FOXA1 in breast cancer is highly correlated with ERalpha+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 acts as a pioneer factor for ERa in ERalpha+ breast cancer, and its expression might identify ERalpha+ cancers that undergo rapid reprogramming of ERa signaling that is associated with poor outcomes and treatment resistance. Conversely, in ERalpha− breast cancer FOXA1 is highly correlated with low-grade morphology and improved disease free survival. FOXA1 is a downstream target of GATA3 in the mammary gland. Expression in ERalpha− cancers may identify a subset of tumors that is responsive to other endocrine therapies such as androgen receptor antagonist treatment. [Wiki]